Tri Chemical Laboratories (4369) Q2 2026 earnings summary

Executive summary

• Net sales for the six months ended July 31, 2025, rose 55.2% year-over-year to ¥12,375 million, with operating profit up 63.9% to ¥3,177 million and profit attributable to owners of parent up 36.7% to ¥2,776 million.

• Comprehensive income increased 30.4% year-over-year to ¥2,840 million for the period.

Financial highlights

• Gross profit increased to ¥4,717 million from ¥3,203 million year-over-year, while operating profit rose to ¥3,177 million from ¥1,939 million.

• Ordinary profit reached ¥3,800 million, up from ¥2,680 million in the prior year period.

• Basic earnings per share increased to ¥85.45 from ¥62.51 year-over-year.

• Cash and deposits at period end were ¥7,096 million, down from ¥9,439 million at the previous fiscal year end.

Outlook and guidance

• Full-year net sales forecast is ¥23,000 million, up 21.7% year-over-year, with operating profit projected at ¥5,500 million (up 4.6%) and profit attributable to owners of parent at ¥4,800 million (down 3.3%).

• Basic earnings per share for the full year is forecast at ¥147.71.

• Annual dividend forecast is ¥35.00 per share.